Jedd D. Wolchok
MD, PhD
Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation
Chief, Melanoma & Immunotherapeutics Service
Associate Director, Ludwig Center for Cancer Immunotherapy & Associate Member, Ludwig Cancer Research
Associate Professor of Medicine, Weill Medical College of Cornell University
Memorial Sloan-Kettering Cancer Center
“The Immune System vs. Cancer”
Dr. Wolchok is currently Chief of the Melanoma and Immunotherapeutics Service, Associate Attending Physician at Memorial Sloan-Kettering Cancer Center (MSKCC) with an expertise in the treatment of metastatic melanoma. His additional appointments include: Head of the Swim Across America Laboratory, one of the foremost immunotherapy and melanoma research groups in the country; Associate Director of the Ludwig Center for Cancer Immunotherapy. Dr. Wolchok has helped establish MSKCC as a leader in the discovery and treatment of cancers with novel immunotherapies. Dr. Wolchok was instrumental in the clinical development leading to the approval of ipilimumab for advanced melanoma. He also leads the MSKCC Immune Monitoring Facility, a world-renowned full-time core dedicated to the pre-clinical and clinical cellular, serological and pathological monitoring of clinical trials of new immunotherapeutic approaches. Currently, he is Principal Investigator of numerous ongoing clinical trials at MSKCC in the area of immunotherapy. In addition, I supervise an R01-funded basic science laboratory which is focused on investigating novel immunotherapeutic agents in pre-clinical mouse models. In 2011, I established the Immunotherapeutics Clinical Core, a specialized phase 1-2 outpatient unit at MSKCC that is focused on the conduct of novel immunotherapy trials, with a specific emphasis on pharmacodynamic biomarker identification. This group treats patients with a broad spectrum of malignancies.
